Definium Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DFTX research report →
Range $52 – $79
Price Chart
About the company
Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD).
- CEO
- Robert Barrow
- IPO
- 2016
- Employees
- 106
- HQ
- New York, NY, US
Get TickerSpark's AI analysis on DFTX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $3.88B
- P/E
- -9.66
- Fwd P/E
- 31.31
- PEG
- 0.20
- P/S
- 0.00
- P/B
- 4.11
- EV/EBITDA
- -11.76
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -54.04%
- ROIC
- -25.25%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+100.0%
- Op Income
- $-166,309,000
- Net Income
- $-183,793,000-69.1%
- EPS
- $-2.06-33.8%
- OCF Growth
- -66.3%
- FCF Growth
- -66.3%
- 52W High
- $49.20
- 52W Low
- $12.88
- 50D MA
- $14.26
- 200D MA
- $14.26
- Beta
- 2.21
- RSI (14)
- 34
- Avg Volume
- 4.53M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Definium said Q3 was an inflection point, with three positive Phase 3 DT120 studies, two FDA breakthrough designations, and over $1 billion in cash to fund a planned NDA filing in the first half of 2027.· November 9, 2026
- Three Phase 3 studies for DT120 in GAD and MDD were positive, with rapid and durable efficacy and no drug-related serious adverse events or suicidality signal in the double-blind phases.
- FDA granted DT120 breakthrough therapy designations in both GAD and MDD, and management said engagement with FDA remains constructive ahead of an NDA planned for 1H 2027.
- Cash, cash equivalents and investments were approximately $1.05 billion at 9/30/2026, and management said that should fund planned operations into 2030.
- DT402 in autism showed encouraging early signals after only 5 participants, supporting continued development and a planned multiday study in 2027.
- Commercial build-out is underway now, including market access, distribution, patient services, field deployment, and physician/site readiness for a potential launch in 2027.
As of 9/30/2026, cash, cash equivalents and investments were approximately $1.05 billion, up from $412 million at 12/31/2025, and management said that should fund planned operations into 2030. R&D expense was $46.1 million in Q3 2026 versus $31 million a year ago, and G&A expense was $26.1 million versus $14.7 million a year ago. Net loss was $51 million versus $67.3 million in Q3 2025. On the clinical side, management reported VOYAGE enrolled 214 participants and showed a 5.4 placebo-adjusted improvement on HAM-A at week 12 with p<0.0001 and Cohen’s d of 0.81; PANORAMA enrolled 245 participants and showed a 5.1 placebo-adjusted improvement with p<0.0001 and Cohen’s d of 0.64; EMERGE met its primary and key secondary endpoints; and DT402’s Phase 2a study stopped after enrolling 5 participants. Management reiterated an NDA filing target in the first half of 2027, with ASCEND top-line data expected in 2027 and HAVEN, the PTSD Phase 3 study, planned for 2027.
Robert Barrow framed Q3 as a major inflection point, emphasizing that DT120 now has a strong evidence base across three positive Phase 3 studies and two breakthrough therapy designations. His tone was confident and urgent, focused on moving from clinical validation to regulatory execution and launch preparation. He also highlighted the early DT402 signal as evidence that the company may have multiple assets and a broader psychiatry pipeline beyond DT120.
Brandi Roberts highlighted a strengthened balance sheet, with approximately $1.05 billion in cash, cash equivalents and investments at quarter-end, and said that based on the current operating plan the company expects funding into 2030. She broke out Q3 spending: R&D rose to $46.1 million from $31 million last year, driven mainly by personnel growth and DT21 development, while G&A rose to $26.1 million from $14.7 million due to corporate/government affairs, commercial readiness, headcount, and legal/patent costs. Net loss narrowed to $51 million from $67.3 million, helped by a change in fair value of the 2022 financing warrant and higher interest income, and she said the company intends to keep investing behind DT120 and launch preparation.
Analysts focused on the pre-NDA meeting timing and whether management would disclose it; Robert Barrow said Definium has regular FDA dialogue, but the company generally shares meeting details after minutes are received. Questions also centered on whether the ASCEND MDD study could affect filing strategy, and management said it will not spell out filing specifics yet but is aiming for the most efficient path to market. Several questions probed commercial strategy, pricing, and competition from other psychedelics programs; management said the Usona filing does not change its approach and reiterated a payer pricing corridor around the $30 thousand to $75 thousand range, while saying it expects to differentiate on product profile and field execution. Analysts also asked about PTSD trial design and DT402 measurement, and management said PTSD will use the CAPS-5 at week 8 with a broad monotherapy study design, while DT402 will use established ASD scales plus additional measures in a collaborative regulatory process.
The call reinforced that DT120 has unusually strong late-stage data, with management citing three positive Phase 3 studies, rapid onset, durability through week 12, and no drug-related serious adverse events or suicidality signal. The balance sheet is also a clear strength, with more than $1 billion in cash and runway into 2030, giving the company room to fund both launch preparation and additional studies. Management sounded confident that it can execute on an NDA in 1H 2027 while building a commercial infrastructure ahead of potential approval.
The key risks are execution-heavy: the company still needs to complete the NDA process, read out ASCEND, and successfully convert promising data into a real launch in a supervised-treatment setting. Management acknowledged that commercial and regulatory specifics are still being held back until later, including filing strategy and how multiple indications may be packaged. DT402 is still very early, based on only 5 participants, so the autism program remains highly preliminary despite the encouraging signals.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 93.5%
- Shares Outstanding
- 136.90M
- Float Shares
- 128.05M
of shares held by institutions
391 13F filers
Buy/sell ratio 4.33. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 11.77M | ▲ 539.76K |
| Fmr LLC | 9.08M | ▲ 4.33M |
| Capital World Investors | 8.26M | ▲ 2.89M |
| Janus Henderson Group Ltd. | 7.20M | ▲ 7.20M |
| Avoro Capital Advisors LLC | 7.05M | ▼ 138.89K |
| Driehaus Capital Management LLC | 6.79M | ▼ 57.25K |
| Jupiter Topco LLC | 5.62M | ▲ 5.62M |
| Price T Rowe Associates Inc | 4.37M | ▼ 285.83K |
| Wellington Management Group Llp | 3.67M | ▲ 722.15K |
| Geode Capital Management, LLC | 3.64M | ▲ 44 |
| State Street Corp | 3.30M | ▲ 235.73K |
| Capital International Investors | 2.98M | ▲ 17.21K |
Held by 258 ETFs
Biggest fund positions in DFTX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 25, 26 | Karlin Daniel | sell | 10,853 |
| Sep 25, 26 | Barrow Robert | sell | 31,550 |
| Sep 25, 26 | Wiley Matthew T. | sell | 3,097 |
| Sep 25, 26 | Sullivan Mark | sell | 14,051 |
| Sep 25, 26 | Roberts Brandi | sell | 3,377 |
| Sep 18, 26 | Vallone Carol A | other | 1,086 |
| Sep 18, 26 | Vallone Carol A | other | 1,086 |
| Sep 18, 26 | Krebs Andreas | other | 1,629 |
| Sep 18, 26 | Krebs Andreas | other | 1,629 |
| Sep 14, 26 | Karlin Daniel | other | 200,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our DFTX coverage
Recent articles, reports, and earnings notes.
No research on DFTX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate DFTX report →Definium Therapeutics Eyes 2027 FDA Filing for LSD-Based Drug, Weighs Two Treatment Paths
marketbeat.com · Nov 20
Definium Therapeutics: 3 Key Takeaways for Long-Term Investors
fool.com · Nov 16
Definium Therapeutics Eyes FDA Filing for LSD Treatment After Three Positive Phase 3 Studies
marketbeat.com · Nov 11
Definium Q3 Earnings: Psychedelics Approval Beckons But Valuation Seems Inflated
seekingalpha.com · Nov 10
Definium Therapeutics, Inc. (DFTX) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 10
What Definium Therapeutics (DFTX) Said on Its Q3 Earnings Call
marketbeat.com · Nov 9
Definium Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights
businesswire.com · Nov 9
Definium Therapeutics Announces New Employee Inducement Grants
businesswire.com · Nov 9
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.